| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Francesco Puppo | |
| Francesca Spanò | |||
| Giuseppe Murdaca | |||
| P2860 | cites work | TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation | Q28513332 |
| Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study | Q34118958 | ||
| TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection | Q34125021 | ||
| The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. | Q34287228 | ||
| Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months | Q34346418 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | Q34544500 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation | Q34608852 | ||
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 | ||
| Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values | Q35760044 | ||
| Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy | Q36151574 | ||
| Emerging biologic drugs for the treatment of rheumatoid arthritis | Q36281242 | ||
| Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). | Q51676058 | ||
| Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. | Q51735851 | ||
| Rheumatoid arthritis | Q56656479 | ||
| Lymphoid neogenesis in rheumatoid synovitis | Q74147962 | ||
| Immunogenicity, efficacy and adverse events of adalimumab in RA patients | Q79151701 | ||
| Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus | Q81516986 | ||
| Serum vascular endothelial growth factor and sublingual immunotherapy | Q81547519 | ||
| Update upon efficacy and safety of TNF-α inhibitors | Q82093052 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment | Q83820129 | ||
| Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events | Q84703479 | ||
| Effects of TNF-α inhibitors upon the mechanisms of action of VEGF | Q86129035 | ||
| Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s | Q36550842 | ||
| Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor | Q36639862 | ||
| Clinical use of anti-TNF-alpha biological agents--a guide for GPs. | Q37030577 | ||
| Vascular effects of biologic agents in RA and spondyloarthropathies | Q37630351 | ||
| The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis | Q37651334 | ||
| Quantifying the economic burden of productivity loss in rheumatoid arthritis | Q37829809 | ||
| The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases | Q37831821 | ||
| Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications | Q37875716 | ||
| Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events | Q37915709 | ||
| Revolutionary change in rheumatoid arthritis management with biological therapy | Q37943237 | ||
| The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review | Q37999872 | ||
| Endothelial dysfunction in rheumatic autoimmune diseases | Q38016726 | ||
| Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs | Q38020459 | ||
| Selective TNF-α inhibitor-induced injection site reactions | Q38075021 | ||
| Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. | Q38107072 | ||
| Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis | Q39710835 | ||
| Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study | Q40079134 | ||
| Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER | Q42677290 | ||
| Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. | Q43049056 | ||
| Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease | Q44118287 | ||
| Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers | Q46138857 | ||
| Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response | Q46650039 | ||
| Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. | Q46802505 | ||
| Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment | Q47239427 | ||
| Oxidation of beta2-glycoprotein I (beta2GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodies | Q49912854 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| adalimumab | Q348260 | ||
| P304 | page(s) | 43-49 | |
| P577 | publication date | 2013-05-07 | |
| P1433 | published in | Open Access Rheumatology: Research and Reviews | Q15816468 |
| P1476 | title | Long-term treatment of rheumatoid arthritis with adalimumab | |
| P478 | volume | 5 |
| Q38192659 | Adalimumab in the treatment of rheumatoid arthritis |
| Q34211985 | Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population |
| Q47159877 | Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance. |
| Q38198080 | Efficacy and safety of etanercept in chronic immune-mediated disease |
| Q48020447 | Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis |
| Q38258624 | Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy |
| Q40081220 | Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis |
Search more.